human
rhinovirus
hrv
member
picornavirida
famili
compris
differ
viru
serotyp
hrv
repres
singl
import
etiolog
agent
common
cold
arruda
e
pitkaranta
witek
jr
tj
doyl
ca
hayden
fg
frequenc
natur
histori
rhinoviru
infect
adult
autumn
gener
understand
pathogenesi
hrvinduc
cold
deriv
primarili
studi
cold
experiment
induc
healthi
adult
volunt
couch
pitkaranta
hayden
turner
et
al
result
studi
suggest
transmiss
hrv
suscept
individu
primarili
direct
contact
viru
also
spread
small
larg
particl
aerosol
anzueto
niederman
viru
deposit
nasal
conjunctiv
mucosa
transport
posterior
nasopharynx
ciliat
epitheli
cell
nasopharynx
viru
attach
epitheli
cell
via
either
intracellular
adhes
hrv
major
serotyp
lowdens
lipoprotein
hrv
minor
serotyp
receptor
initi
infect
examin
biopsi
specimen
nasal
epithelium
immunofluoresc
situ
hybrid
techniqu
demonstr
infect
small
number
cell
littl
chang
morpholog
integr
nasal
epithelium
couch
pitkaranta
hayden
turner
et
al
find
consist
hypothesi
symptom
common
cold
due
elabor
inflammatori
mediat
rather
direct
lytic
effect
host
cell
naclerio
et
al
pitkaranta
hayden
turner
et
al
although
initi
symptom
appear
earli
h
symptom
develop
day
infect
peak
day
rapidli
resolv
within
one
week
gwaltney
gwaltney
et
al
harri
gwaltney
rao
et
al
symptom
includ
rhinorrhea
nasal
congest
sore
throat
headach
cough
malais
lowgrad
fever
median
time
onset
viru
shed
nasal
secret
report
h
peak
viru
titer
occur
day
inocul
certain
percentag
individu
viru
detect
week
infect
close
tempor
associ
viru
replic
initi
inflammatori
cascad
symptom
develop
combin
rapid
resolut
ill
pose
perhap
one
biggest
challeng
antivir
chemotherapi
kinet
suggest
antivir
agent
demonstr
optim
therapeut
effect
would
administ
earli
infect
altern
approach
combin
antivir
agent
agent
suppress
inflamm
also
describ
gwaltney
et
al
repres
strategi
may
requir
extens
review
result
deriv
publish
unpublish
randomis
control
trial
chemotherapeut
agent
intervent
hrvinduc
upper
respiratori
diseas
detail
jefferson
tyrrel
two
gener
studi
design
util
includ
experiment
human
challeng
model
natur
cold
studi
rao
et
al
sperber
hayden
absenc
practic
anim
model
hrv
experiment
human
challeng
model
use
frequent
studi
viru
pathogenesi
viru
transmiss
effect
drug
control
condit
model
serosuscept
human
volunt
inocul
defin
inoculum
safetytest
hrv
treat
drug
either
viru
challeng
subject
isol
individu
room
symptom
report
done
standard
condit
object
measur
may
includ
level
infecti
viru
viru
rna
nasal
wash
mucu
weight
although
number
specif
safetytest
hrv
serotyp
limit
rate
infect
ill
vari
studi
studi
model
effect
establish
initi
proof
concept
antivir
agent
sinc
sensit
rapid
diagnost
hrv
exist
could
allow
prospect
enrol
hrv
posit
subject
natur
cold
studi
depend
success
recruit
individu
present
specif
respiratori
symptom
wide
variat
durat
sever
ill
follow
infect
patient
inclus
criteria
relat
symptomatolog
must
care
consid
optim
detect
treatment
effect
addit
critic
enrich
popul
infect
hrv
although
infect
hrv
occur
throughout
year
peak
hrvinduc
ill
northern
hemispher
well
describ
earli
autumn
spring
hrv
also
frequent
isol
viru
summer
month
howev
overal
incid
ill
low
monto
base
inform
natur
infect
studi
northern
hemispher
typic
target
fall
spring
month
base
tight
associ
viru
replic
symptom
develop
subsequ
ill
resolut
import
patient
enrol
earli
h
follow
symptom
develop
order
maxim
opportun
see
treatment
effect
analys
viru
sampl
perform
retrospect
precis
defin
hrv
posit
patient
popul
convent
method
detect
quantifi
hrv
nasal
sampl
studi
subject
viru
cultur
combin
instanc
measur
acid
labil
couch
culturebas
method
though
typic
suffici
sensit
discrimin
rigor
detect
immunolog
method
also
describ
eg
optic
immunoassay
limit
either
inabl
recogn
multipl
serotyp
base
high
variabl
region
util
antigen
product
eg
capsid
protein
multiserotyp
recognit
achiev
degre
time
virusinduc
antigen
nasal
aspir
ostroff
et
al
sensit
specif
method
base
rtpcr
recent
describ
hayden
et
al
b
go
forward
interest
util
rtpcr
methodolog
readdress
issu
relat
hrv
pathogenesi
kinet
viru
replic
diseas
etiolog
hrv
respiratori
diseas
incid
rate
hrvinduc
ill
chemotherapeut
approach
toward
hrvinduc
ill
focu
intens
research
span
sever
decad
comprehens
review
small
molecul
inhibitor
target
specif
viru
function
includ
viru
attach
uncoat
viru
rna
replic
viral
protein
synthesi
process
extens
detail
carrasco
patick
pott
shih
et
al
sperber
hayden
antivir
agent
direct
toward
viru
attach
capsid
uncoat
proteas
well
agent
indirectli
impair
viral
replic
eg
interferon
best
studi
primari
focu
subsequ
section
interferon
mediat
antivir
anticanc
immunomodulatori
effect
specif
receptorsign
transduct
pathway
sever
studi
evalu
efficaci
recombin
interferon
alpha
prevent
treatment
hrvinduc
cold
hayden
et
al
rotbart
sperber
hayden
studi
intranas
interferon
shown
effect
experiment
natur
cold
provid
prophylact
littl
effect
develop
infect
symptom
provid
infect
mani
studi
interferon
associ
vari
side
effect
includ
appear
bloodting
mucu
nasal
mucos
bleed
hrv
serotyp
util
receptor
attach
suscept
host
cell
strategi
prevent
viru
attach
receptor
blockad
util
solubl
form
extens
evalu
vitro
clinic
studi
turner
et
al
turner
tremacamra
develop
boehring
ingelheim
evalu
random
doubleblind
experiment
infect
trial
studi
patient
receiv
tremacamra
formul
either
nasal
spray
solut
inhal
powder
h
h
viru
challeng
time
day
day
turner
et
al
although
magnitud
effect
small
tremacamra
shown
reduc
sever
experiment
cold
given
either
hrv
challeng
although
result
interest
potenti
issu
may
includ
challeng
demonstr
efficaci
provid
later
h
infect
possibl
antibodi
respons
poor
toler
patient
complianc
associ
time
daili
administr
develop
current
report
agent
hrv
capsid
consist
denselypack
icosahedr
arrang
protom
consist
protein
locat
viral
surfac
locat
inner
surfac
remain
close
associ
rna
core
function
anchor
viru
capsid
elucid
solv
threedimension
crystal
structur
hrv
reveal
canyon
form
junction
rossmann
et
al
beneath
canyon
within
lie
pore
lead
hydrophob
pocket
occupi
pocket
factor
propos
fatti
acid
numer
molecul
divers
chemic
class
describ
vitro
antivir
activ
hrv
bind
region
carrasco
shih
et
al
antivir
activ
relat
abil
prevent
viral
attach
andor
uncoat
presum
prevent
capsid
destabil
subsequ
releas
rna
cytoplasm
vitro
capsidbind
typic
activ
hrv
serotyp
possess
wide
rang
suscept
variabl
suscept
serv
basi
one
method
classif
hrv
serotyp
two
differ
group
b
andri
et
al
first
capsidbind
compound
synthes
extens
studi
includ
seri
oxazolinyl
isoxazol
win
compound
sterl
winthrop
pharmaceut
group
first
compound
advanc
clinic
trial
disoxaril
win
preclin
studi
disoxaril
demonstr
vitro
antivir
activ
enterovirus
hrv
shown
reduc
mortal
polioviru
infect
mice
paralysi
echoviru
infect
mice
subsequ
develop
crystallurea
human
volunt
treat
high
dose
prohibit
subsequ
develop
efficaci
oral
administ
win
next
gener
compound
evalaut
prevent
hrv
infect
ill
two
experiment
studi
human
volunt
inocul
either
hrv
hrv
turner
et
al
win
administ
time
viru
challeng
mg
dose
time
day
subsequ
day
signific
antivir
clinic
effect
detect
either
studi
pharmacokinet
studi
reveal
last
day
drug
administr
infect
subject
total
plasma
trough
level
correct
protein
bind
win
greater
minim
inhibitori
concentr
appropri
viru
detect
level
drug
nasal
wash
specimen
subject
find
suggest
appropri
level
drug
may
present
site
viru
replic
although
win
reduc
number
sever
cold
administ
prophylact
human
challeng
coxsackieviru
cav
rotbart
develop
compound
discontinu
primarili
due
advers
effect
flush
rash
subsequ
synthet
chemistri
effort
led
discoveri
pleconaril
win
picovir
oral
bioavail
analogu
potent
broadspectrum
activ
wide
varieti
enteroviru
hrv
serotyp
clinic
isol
pevear
et
al
kaiser
et
al
patick
et
al
date
pleconaril
repres
first
compound
submit
us
food
drug
administr
fda
regulatori
approv
experiment
induc
cav
model
involv
subject
pleconaril
demonstr
statist
signific
reduct
viru
shed
nasal
mucu
product
total
respiratori
ill
symptom
score
administ
oral
mg
dose
twice
day
day
schiff
sherwood
pleconaril
subsequ
evalu
two
phase
ii
placebocontrol
natur
cold
trial
hayden
et
al
involv
healthi
individu
present
within
h
respiratori
symptom
onset
month
julydecemb
first
trial
subject
receiv
g
pleconaril
placebo
either
liquid
tablet
formul
time
day
day
sinc
number
picornavirusposit
subject
lower
expect
first
second
trial
respect
dataset
combin
analys
among
subset
subject
proven
picornaviru
infect
pleconaril
provid
day
reduct
time
allevi
ill
compar
placebo
pleconaril
gener
well
toler
associ
gastrointestin
disturb
group
receiv
liquid
formul
greater
incid
nausea
group
receiv
tablet
compar
placebo
two
subsequ
pivot
studi
pleconaril
produc
moder
reduct
day
median
time
allevi
ill
among
picornavirusposit
subject
treat
pleconaril
compar
placebo
hayden
et
al
b
subject
studi
enrol
within
h
symptom
onset
picornavir
resist
identifi
total
patient
baselin
isol
suscept
pleconaril
develop
reduc
suscept
defin
chang
baselin
valu
cours
day
treatment
relev
pleconaril
resist
shown
subsequ
studi
pevear
et
al
patient
viru
isol
measur
baselin
suscept
ec
viru
gml
deriv
clinic
benefit
pleconaril
treatment
convers
emerg
viru
reduc
suscept
therapi
associ
measur
advers
clinic
consequ
pevear
et
al
subsequ
prophylaxi
studi
pleconaril
found
induc
led
intermenstru
bleed
menstrual
abnorm
women
take
estrogenbas
oral
contracept
hayden
et
al
b
fleischer
laessig
march
antivir
drug
advisori
committe
fda
vote
recommend
pleconaril
approv
treatment
cold
adult
primarili
base
drug
interact
margin
treatment
effect
possibl
transmiss
resist
viru
although
develop
pleconaril
oral
deliveri
discontinu
scheringplough
licens
viropharma
develop
intranas
formul
pleconaril
potenti
treatment
common
cold
highrisk
popul
capsidbind
well
studi
includ
pirodavir
r
substitut
phenoxypyridazinamin
develop
janssen
research
foundat
earlier
compound
r
repres
first
compound
demonstr
efficaci
prevent
experiment
cold
human
challeng
experi
alnakib
et
al
safeti
efficaci
intranas
pirodavir
evalu
doubleblind
control
trial
experiment
hrv
infect
hayden
et
al
three
prophylaxi
studi
subject
inocul
hrv
within
min
second
third
dose
pirodavir
shown
effect
decreas
infect
defin
viral
shed
andor
seroconvers
develop
clinic
cold
administ
six
time
day
two
addit
trial
pirodavir
administr
three
time
day
fourth
trial
pirodavir
abl
reduc
viru
shed
demonstr
clinic
benefit
administ
h
challeng
overal
intranas
pirodavir
well
toler
associ
unpleas
tast
nasal
dryness
subsequ
natur
infect
trial
pirodavir
administ
six
time
daili
day
adult
exhibit
symptom
h
less
signific
differ
observ
resolut
respiratori
symptom
median
durat
ill
howev
signific
differ
frequenc
viru
shed
reason
discord
viru
replic
symptomolog
studi
unknown
develop
compound
discontinu
hrv
contain
singl
strand
posit
sens
rna
kb
length
contain
singl
open
read
frame
encod
singl
polyprotein
amino
acid
follow
initi
cleavag
viral
encod
proteas
releas
major
subsequ
cleavag
mediat
viral
encod
proteas
patick
pott
date
sever
differ
compound
target
proteas
describ
patick
pott
shih
et
al
rupintrivir
formerli
intranas
administ
irrevers
inhibitor
incorpor
unsatur
ethyl
ester
michael
acceptor
matthew
et
al
vitro
rupintrivir
demonstr
potent
activ
hrv
serotyp
hrv
clinic
isol
enterovirus
test
kaiser
et
al
binford
et
al
broadspectrum
activ
togeth
narrow
rang
suscept
consist
dna
sequenc
analys
perform
proteasecod
gene
region
demonstr
signific
level
homolog
substrateinhibitor
bind
region
meador
et
al
binford
et
al
human
experiment
hrv
challeng
trial
rupintrivir
abl
moder
sever
ill
reduc
viral
load
provid
proof
concept
mechan
proteas
inhibit
hayden
et
al
b
subsequ
natur
infect
studi
patient
rupintrivir
abl
significantli
effect
viru
reduct
moder
diseas
sever
thu
termin
clinic
develop
subsequ
effort
discov
oral
bioavail
inhibitor
proteas
result
identif
compound
also
irrevers
inhibitor
proteas
potent
vitro
activ
hrv
serotyp
enterovirus
test
dragovich
et
al
patick
et
al
phase
ascend
singledos
studi
healthi
volunt
compound
shown
safe
well
toler
free
observ
maximum
concentr
plasma
higher
effect
concentr
requir
inhibit
hrv
serotyp
current
clinic
develop
plan
compound
despit
extens
research
effort
led
discoveri
mani
potent
antivir
agent
drug
today
approv
treatment
prevent
hrvinduc
ill
mani
factor
consid
tri
understand
shortcom
major
individu
hrvinduc
cold
mild
selflimit
alon
dictat
agent
must
safe
toler
high
risk
benefit
ratio
specif
agent
must
limit
side
effect
low
risk
resist
develop
must
administ
accept
level
frequenc
eg
less
three
time
day
date
agent
abl
achiev
three
criteria
demonstr
appropri
clinic
efficaci
drug
formul
topic
intranas
administr
often
provid
multipl
daili
dose
overcom
mucociliari
clearanc
mechan
act
clear
drug
quickli
nasal
caviti
type
administr
formul
must
care
consid
allow
appropri
drug
deposit
dissolut
within
nasal
caviti
physiochem
properti
drug
allow
prolong
resid
time
intracellular
accumul
residu
biolog
activ
may
requir
appropri
antivir
effect
addit
although
drug
level
measur
nasal
wash
use
predict
pharmacokinet
good
technolog
exist
allow
direct
assess
drug
level
intracellularli
site
viru
replic
case
drug
efficaci
typic
first
realiz
trial
infect
patient
infecti
viru
rna
level
measur
clinic
symptom
score
oral
administ
drug
level
easili
measur
plasma
valu
assum
correl
level
nasal
epithelium
oral
administr
amen
conveni
dose
regimen
may
allow
compound
access
addit
hrv
replic
site
avail
nasal
deliveri
howev
oral
deliveri
may
also
increas
risk
side
effect
rel
nasal
topic
deliveri
observ
pleconaril
clinic
studi
demonstr
efficaci
clinic
studi
natur
infect
also
challeng
rapid
onset
symptom
patient
must
enrol
trial
initi
antivir
therapi
within
h
maxim
opportun
therapeut
intervent
antivir
ultim
approv
hrvinduc
common
cold
requir
almost
immedi
diagnosi
provis
prescript
patient
physician
although
hurdl
associ
drug
approv
hrvinduc
ill
signific
encourag
drug
develop
hrv
also
possess
broadspectrum
activ
picornavirus
includ
polioviru
instanc
virus
famili
homolog
protein
eg
sar
matthew
et
al
situat
encourag
think
drug
develop
hrv
may
also
abl
impact
diseas
